Based on the cash flow, Recce is running on fumes.
Basically relying on R&D advances for funds.
Unless the company:
• raises more cash
• is bought out
• enters into some form of arrangement with a large pharma
the end is near.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.005(0.97%) |
Mkt cap ! $120.4M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 52.0¢ | 50.5¢ | $64.18K | 124.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 216812 | 50.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 9 | 1 |
View Market Depth
| Last trade - 16.10pm 24/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |